MedPath

Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin

Recruiting
Conditions
Neurocognitive Disorders
Registration Number
NCT06463093
Lead Sponsor
Central Hospital, Nancy, France
Brief Summary

The aim of the research is to analyze whether 18F-FDG PET helps in the diagnosis and therefore in the management of the patient.

Detailed Description

Neurocognitive disorder or Mild Cognitive Impairment corresponds to a decline in one or more cognitive functions; compared to the previous level of performance.

Indeed, the prevalence of neurodegenerative pathologies is estimated at more than one million according to Santé Publique France, due to the aging of the population. To be compared with the prevalence of the population suffering from a psychiatric disorder estimated at one in five people, or 13 million French people, in 2021.

With the increase in the prevalence of these two entities and their clinical entanglement, the question arises of the origin of neurocognitive disorders, is it a manifestation of a psychiatric pathology or a neurodegenerative pathology not yet diagnosed.

If this is the case, the patient's prognosis is modified with a pejorative evolution and a loss of autonomy which is to be anticipated. This delay deprives the patient and his family of interventions likely to alleviate behavioral disorders; maintain a level of autonomy compatible with life at home; alleviates the burden and improves the quality of life of caregivers.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Adult patients with cognitive impairment
  • Positron emission tomography with flurodeoxyglucose labeled with fluorine 18 carried out in the course of care
Exclusion Criteria
  • Patients objecting to the collection of their data

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Neuro cognitive disorders and disorders of neurodegenerative origin in psychiatric populationone day

Change of the diagnosis before the PET and after the PET

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Nancy's hospital

🇫🇷

Vandœuvre-lès-Nancy, France

© Copyright 2025. All Rights Reserved by MedPath